-
36th Annual
Roth Conference – March17-19,Dana Point, California , USA
This event provides investors the opportunity to hear from and meet with executive management from approximately 500 private and public companies.
-
Bio-Europe Spring – March18-20,
Barcelona, Spain
This is the premier springtime partnering event, bringing together over 2,000+ companies to engage in one-to-one meetings.
-
Congrès de la Société Francophone du diabète – March19-22,
Toulouse, France
This congress covers all aspects of modern diabetology, from fundamentals to clinical practice, with a special focus on therapeutic and technological innovations and e-health.
-
Investor Access –
April 4-5 ,Paris, France
This event is dedicated to individual shareholder and brings together companies and investors for two days of conferences and pre-hosted meetings.
-
Cell and Gene Meeting on the Med -
April 9-11 ,Roma, Italy
This is the leading conference bringing together the cell and gene therapy sector. Covering a wide range of topics (from market access to regulatory, manufacturing or financing), this program features expert-led panels, one-on-one partnering capabilities, presentations by leading companies.
-
LSX World Congress –April 29-30 ,London, UK
The event brings together the CEOs and senior decision makers from the world's most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs.
-
Equity Forum Spring – May13-15,Frankfurt, Germany
Around 120 listed companies fromGermany and abroad attend this event to present their latest business figures and outlooks for the following financial year to selected investors, analysts, financial journalists and other capital market players.
About
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.
Disclaimer
This press release contains certain forward-looking statements concerning
The forward-looking statements contained in this press release are also subject to risks not yet known to
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306184245/en/
CEO
contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
Ulysse Communication
adocia@ulysse-communication.com
+ 33 (0)6 64 79 97 51
Source: